Subscribe
shutterstock_634750544_felixlipov
felixlipov / Shutterstock.com
23 April 2020AmericasSarah Morgan

Fed Circuit rejects Biogen’s plea in MS drug dispute

The US Court of Appeals for the Federal Circuit has affirmed a lower court’s decision which found that  Banner Life Sciences wasn’t infringing a  Biogen patent with its bioequivalent version of a multiple sclerosis drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29 September 2020   The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Americas
Biogen takes Creative Biolabs to court over antibody
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29 September 2020   The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Americas
Biogen takes Creative Biolabs to court over antibody
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.

More on this story

Americas
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29 September 2020   The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
Americas
Biogen takes Creative Biolabs to court over antibody
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB